Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Jun 2025 value amounting to $26,000.

  • Catalyst Pharmaceuticals' Capital Expenditures rose 160.00% to $26,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $383,000, marking a year-over-year increase of 4.64%. This contributed to the annual value of $556,000 for FY2024, which is 140.69% up from last year.
  • According to the latest figures from Q2 2025, Catalyst Pharmaceuticals' Capital Expenditures is $26,000, which was down 70.45% from $88,000 recorded in Q4 2024.
  • Catalyst Pharmaceuticals' 5-year Capital Expenditures high stood at $911,000 for Q1 2021, and its period low was $1,000 during Q2 2021.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Capital Expenditures value was $81,000 (recorded in 2023), while the average stood at $101,625.
  • The largest annual percentage gain for Catalyst Pharmaceuticals' Capital Expenditures in the last 5 years was 304.69% (2024), contrasted with its biggest fall of 5.38% (2024).
  • Catalyst Pharmaceuticals' Capital Expenditures (Quarterly) stood at $41,000 in 2021, then reached $93,000 in 2023, then decreased by 5.38% to $88,000 in 2024, then surged by 160.00% to $26,000 in 2025.
  • Its Capital Expenditures was $26,000 in Q2 2025, compared to $88,000 in Q4 2024 and $259,000 in Q3 2024.